| Bioactivity | Sampeginterferon beta-1a (BCD-054) is a pegylated IFNβ-1a. Sampeginterferon beta-1a can be used for research against remitting multiple sclerosis[1][2]. |
| Name | Sampeginterferon beta-1a |
| CAS | 1796570-07-4 |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Boyko AN, et al. Novyĭ pegilirovannyĭ interferon beta-1a (sampéginterferon beta-1a, BCD-054) v terapii remittiruiushchego rasseiannogo skleroza [The new pegylated interferon beta-1a (sampeginterferon beta-1a, BCD-054) in the treatment of remitting multiple sclerosis]. Zh Nevrol Psikhiatr Im S S Korsakova. 2019;119(10. Vyp. 2):100-109. Russian. [2]. Boyko A N. Ways to improve adherence to long-term injection therapy in multiple sclerosis using the example of pegylated interferon-β1a (sampeginterferon β-1a)[J]. Neurology, Neuropsychiatry, Psychosomatics, 2022, 14(1S): 34-37. |